SEC 13F Intelligence

Managers / Q1 2021 · view latest →

Opaleye Management Inc.

CIK 0001595855 · ONE BOSTON PLACE, SUITE 2600, BOSTON, MA, 02108 · 617-904-9195

Reported Value
$681M
Q1 2021
Positions
58
Filings on Record
33
2019–present window
Filed
May 18, 2021
original filing

Summary

Opaleye Management Inc. reported $681M in U.S.-listed holdings across 58 positions for Q1 2021.

Its largest position, OCUL, represents 15.6% of the portfolio.

Compared with Q4 2020, the fund opened 15 new positions and exited 16.

Portfolio Metrics

Turnover
+26.0%
vs prior filed quarter
Top-10 Concentration
+54.4%
share of reported value
Largest Position
+15.6%
Ocular Therapeutix
New / Exited
15 / 16
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $268MQ4 ’18Q1 ’19: $361MQ2 ’19: $328MQ3 ’19: $277MQ4 ’19: $510MQ4 ’19Q1 ’20: $377MQ2 ’20: $495MQ3 ’20: $511MQ4 ’20: $766MQ4 ’20Q1 ’21: $681MQ2 ’21: $602MQ3 ’21: $535MQ4 ’21: $471MQ4 ’21Q1 ’22: $322MQ2 ’22: $222MQ3 ’22: $242MQ4 ’22: $288MQ4 ’22Q1 ’23: $334MQ2 ’23: $418MQ3 ’23: $307MQ4 ’23: $376MQ4 ’23Q1 ’24: $459MQ2 ’24: $438MQ3 ’24: $600MQ4 ’24: $571MQ4 ’24Q1 ’25: $449MQ2 ’25: $494MQ3 ’25: $707MQ4 ’25: $758MQ4 ’25Q1 ’26: $759Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 78.5%Other: 19.3%ADR: 2.2%
  • Common Stock · 78.5% · $535M
  • Other · 19.3% · $131M
  • ADR · 2.2% · $15M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BBIOBRIDGEBIO PHARMA INCNEW+583.8K583.8K+$36M$36M
AUTLAUTOLUS THERAPEUTICS PLCNEW+2.11M2.11M+$12M$12M
GEMINI THERAPEUTICS INCNEW+810.5K810.5K+$11M$11M
KROSKEROS THERAPEUTICS INCNEW+157.5K157.5K+$10M$10M
CKPTUSDCHECKPOINT THERAPEUTICS INCNEW+2.93M2.93M+$9M$9M
PROQR THERAPEUTICS NVNEW+1.30M1.30M+$9M$9M
IMVTIMMUNOVANT INCNEW+467.0K467.0K+$7M$7M
SMTISANARA MEDTECH INCNEW+225.0K225.0K+$7M$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1OCULOCULAR THERAPEUTIX INChistory →COM15.62%$106M6.48M
2CMRXEURCHIMERIX INChistory →COM6.36%$43M4.49M
3TARAPROTARA THERAPEUTICS INChistory →COM STK5.92%$40M2.56M
4BBIOBRIDGEBIO PHARMA INChistory →COM5.28%$36M583.8K
5CDXSCODEXIS INChistory →COM4.71%$32M1.40M
6ETONETON PHARMACEUTICALS INChistory →COM4.34%$30M4.04M
7MGNXMACROGENICS INChistory →COM3.12%$21M666.2K
8TRACON PHARMACEUTICALS INCCOM NEW3.04%$21M2.52M
9HROWHARROW HEALTH INChistory →COM3.04%$21M3.07M
10TCE2CELLDEX THERAPEUTICS INChistory →COM NEW2.98%$20M985.0K
11X0M1XOMA CORP DELhistory →COM NEW2.62%$18M437.5K
12RJR1STEREOTAXIS INChistory →COM NEW2.49%$17M2.53M
13NEOLEUKIN THERAPEUTICS INCCOM2.22%$15M1.23M
14FORTRESS BIOTECH INCCOM2.01%$14M3.88M
15CYTKCYTOKINETICS INChistory →COM NEW1.98%$13M580.0K
16AUTLAUTOLUS THERAPEUTICS PLChistory →SPONSORED ADS1.78%$12M2.11M
17GEMINI THERAPEUTICS INCCOM1.61%$11M810.5K
18DCPHEURDECIPHERA PHARMACEUTICALS INhistory →COM1.46%$10M222.0K
19MCRB1EURSERES THERAPEUTICShistory →COM1.44%$10M300.0K
20KROSKEROS THERAPEUTICS INChistory →COM1.42%$10M157.5K
21CKPTUSDCHECKPOINT THERAPEUTICS INChistory →COM1.35%$9M2.93M
22PROQR THERAPEUTICS NVSHS EURO1.27%$9M1.30M
23EPIEURESSA PHARMA INChistory →COM NEW1.21%$8M284.1K
24AFIBACUTUS MEDICAL INChistory →COM1.21%$8M615.0K
25ADMSEURADAMAS PHARMACEUTICALS INChistory →COM1.18%$8M1.67M
26CERECOR INCCOM1.15%$8M2.60M
27SUTRO BIOPHARMA INCCOM1.14%$8M341.9K
28PTGXPROTAGONIST THERAPEUTICS INChistory →COM1.13%$8M297.0K
29IMVTIMMUNOVANT INChistory →COM1.10%$7M467.0K
30PCVXVAXCYTE INChistory →COM1.04%$7M357.8K
31SMTISANARA MEDTECH INChistory →COM1.03%$7M225.0K
32CATALYST BIOSCIENCES INCCOM NEW0.93%$6M1.25M
33AVEO BIOSCIENCES INCCOM NEW0.90%$6M835.0K
34KINIKSA PHARMACEUTICALS LTDCOM CL A0.87%$6M320.9K
35VERASTEM INCCOM0.84%$6M2.33M
36TELATELA BIO INCCOM0.80%$5M365.0K
37MEI PHARMA INCCOM NEW0.78%$5M1.56M
38CRDFCARDIFF ONCOLOGY INCCOM0.78%$5M576.0K
39AXONEURSIO GENE THERAPIES INCCOM0.77%$5M2.00M
40APTOSE BIOSCIENCES INCCOM NEW0.77%$5M871.8K
41MYOVANT SCIENCES LTDCOM0.76%$5M249.8K
42FGENEURFIBROGEN INCCOM0.75%$5M147.0K
43LUMOS PHARMA INCCOM0.65%$4M376.9K
44KEZAR LIFE SCIENCES INCCOM0.62%$4M711.2K
45OPTINOSE INCCOM0.45%$3M826.0K
46HIGHCAPE CAPITAL ACQUISITION CORPCOM CL A0.42%$3M241.3K
47CRNXCRINETICS PHARMACEUTICALS INCCOM0.42%$3M188.0K
48EDAEDAP TMS SASPONSORED ADR0.42%$3M341.3K
49SIERRA ONCOLOGY INCCOM NEW0.38%$3M151.1K
50BIOHAVEN PHARMACEUTICAL HLDGCOM0.25%$2M25.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$759M54May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$758M54Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$707M43Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$494M41Aug 15, 2025RESTATEMENTchanges · EDGAR ↗
Q1 2025$449M45May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$571M39Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$600M44Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$438M51Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$459M52May 29, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$376M47Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$307M41Nov 15, 202313F-HRchanges · EDGAR ↗
Q2 2023$418M47Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$334M41May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$288M40Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$242M42Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$222M47Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$322M45May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$471M39Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$535M48Nov 16, 202113F-HRchanges · EDGAR ↗
Q2 2021$602M48Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$681M58May 18, 202113F-HRchanges · EDGAR ↗
Q4 2020$766M59Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$511M55Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$495M48Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$377M44May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$510M47Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$277M49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$328M43Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$361M53May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$268M47Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.